A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy, safety, and immunogenicity of an
investigational vaccine being developed for the treatment of leishmaniasis, including
cutaneous leishmaniasis (CL). The vaccine, identified as LEISH-F2 + MPL-SE, consists of a
Leishmania protein (LEISH-F2) together with an adjuvant MPL-SE.